Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.45 |
| ▸ | RARG | P13631 | 4/20 | 0.45 |
| ▸ | RARA | P10276 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657117 | 0.85 | NOTUM (0.45) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL5656647 | 0.84 | NOTUM (0.44) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL5654523 | 0.81 | NOTUM (0.42) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL9617566 | 0.80 | GAA (0.47) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL9617620 | 0.79 | PTGS1 (0.41) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL987763 | 0.76 | RARB (0.41) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL23554960 | 0.76 | PKM (0.55) | CA1CA2CA12ALDH1A1PKM | |
| SCHEMBL987764 | 0.75 | PTGS1 (0.43) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL8982307 | 0.74 | NOTUM (0.49) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL3542625 | 0.72 | RARB (0.71) | RARBRARGRARAPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196108-B2 | Bicyclic heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1487446-A4 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1487446-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003075858-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
| CN-1312680-A | Herbicidal compositions containing acylated aminophenylsulfonylureas | AVENTIES CROP SCIENCES GMBH (DE) | 2001-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | PC, CYP27A1, GPR119 | RARB 3268/4885RARG 1834/4885RARA 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.